Renal microRNA- and RNA-profiles in progressive chronic kidney disease.
Innsbruck, Austria. In Eur J Clin Invest, Jan 2016
In particular miR-206 and miR-532-3p were associated with distinct biological processes via the expression of their target mRNAs: Reduced expression of miR-206 in progressive disease correlated with the upregulation of target mRNAs participating in inflammatory pathways (CCL19, CXCL1, IFNAR2, NCK2, PTK2B, PTPRC, RASGRP1, and TNFRSF25).
Small Molecule Agonists for the Type I Interferon Receptor: An In Silico Approach.
Toronto, Canada. In J Interferon Cytokine Res, Jan 2016
Cognizant that the biological potency of an IFN-α subtype is determined by its binding affinity to the type I IFN receptor, IFNAR, we identified a panel of small molecule nonpeptide compounds using an in silico screening strategy that incorporated specific structural features of amino acids in the receptor-binding domains of the most potent IFN-α, IFN alfacon-1.